|  |
| --- |
| **Checklist for submitting comments.**   * Use this comments form and submit it as a **Word document (not a PDF)**. * **Do not submit further attachments** such as research articles, or supplementary files. We return comments forms that have attachments without reading them. You may resubmit the form without attachments, but it must be received by the deadline. You are welcome to include links to research articles or provide references to them. * Complete the disclosure about links with, or funding from, the tobacco industry. * Include **page number and section number** of the text each comment is about. * Combine all comments from your organisation into 1 response form. **We cannot accept more than 1 response from each organisation**. * **Do** **not** paste other tables into this table – type directly into the table. * Ensure each comment stands alone; **do not** cross-refer within one comment to another comment. * **Clearly mark any confidential information or other material that you do not wish to be made public with underlining and highlighting. Also, ensure you state in your email to NICE, and in the row below, that your submission includes confidential comments.** * **Do not name or identify any person or include medical information about yourself or another person** from which you or the person could be identified as all such data will be deleted or redacted. * Spell out any abbreviations you use. * **We do not accept comments submitted after the deadline stated for close of consultation.** |

|  |  |
| --- | --- |
|  | **Please read the checklist above before submitting comments.** **We cannot accept forms that are not filled in correctly.**  A process is needed to rapidly update the technology appraisal recommendations on medicines for COVID-19. This may be in response to several triggers including new clinical evidence, a change in the disease that significantly changes hospitalisation or mortality rates or emergence of a new variant of SARS-CoV-2 that affects the effectiveness of a medicine. A process statement has been developed that outlines the methods and process that will be used for surveillance and updates to recommendations.  We would like to hear your views on the following questions. **Please include your answers to these questions with your comments in the table below:**   1. **Is the process as outlined a good basis for the committee to make decisions and update recommendations?** 2. **Do you have any concerns about the process and, if so, any suggestions to address those concerns?** 3. **Do you feel there are any gaps in the process or areas that need further consideration?** |
| Organisation name (if you are responding as an individual rather than a registered stakeholder please specify). | [**Insert organisation name or “individual”**] |
| Disclosure (please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry). | [**Insert disclosure here**] |
| Confidential comments (Do any of your comments contain confidential information?) | Yes/No [please delete as applicable] |
| Name of person completing form | [**Insert your name here**] |

|  |  |  |  |
| --- | --- | --- | --- |
| **Comment number** | Page number  **‘General’** for comments on whole document | Section number  **‘General’** for comments on whole document | Comments  * Insert each comment in a new row. * Do not paste other tables into this table, because your comments could get lost – type directly into this table. * Include section or recommendation number in this column. |
| Example | 016 | 1.2.2 | We are concerned that this approach may imply that ………….. |
| Example | 010 | 2.4.6 | We agree with the timescales listed, and would also like to add …. |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 |  |  |  |
| 5 |  |  |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 8 |  |  |  |
| 9 |  |  |  |
| 10 |  |  |  |

Insert extra rows as needed

**Data protection**

The information you submit on this form will be retained and used by NICE and its advisers for the purpose of developing its guidance and may be passed to other approved third parties.Please do not name or identify any individual patient or refer to their medical condition in your comments as all such data will be deleted or redacted. The information may appear on the NICE website in due course in which case all personal data will be removed in accordance with NICE policies.

By submitting your data via this form you are confirming that you have read and understood this statement.

For more information about how we process your data, please see our [privacy notice](https://www.nice.org.uk/privacy-notice).